Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C

In this small, preliminary study of sofosbuvir, a nucleotide inhibitor of HCV polymerase, treatment with sofosbuvir and ribavirin, without peginterferon, was effective in achieving a sustained virologic response in patients with HCV genotype 1, 2, or 3 infection. Recent progress in the treatment of chronic hepatitis C virus (HCV) infection — the approval of the first-generation protease inhibitors telaprevir and boceprevir — has benefited many but not all patients with HCV infection. One quarter of patients with HCV genotype 1 infection who have not received previous therapy and 71% of those with no response to previous therapy do not have a sustained virologic response with protease-inhibitor–based regimens. 1 No direct-acting antiviral agents have yet been approved for patients with HCV genotype 2 or 3 infection. The standard of care for all patients with HCV infection continues to include 24 . . .